Policy for the use of multiple dose vials of injectable medication

<table>
<thead>
<tr>
<th>Approved By:</th>
<th>Policy &amp; Guidelines Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of Original Approval:</td>
<td>8th September 2008</td>
</tr>
<tr>
<td>Trust Reference:</td>
<td>B42/2008</td>
</tr>
<tr>
<td>Version:</td>
<td>4</td>
</tr>
<tr>
<td>Supersedes:</td>
<td>3 – January 2016</td>
</tr>
<tr>
<td>Trust Lead:</td>
<td>Elizabeth McKechnie, Medication Safety Lead Pharmacist</td>
</tr>
<tr>
<td>Board Director Lead:</td>
<td>Dr Andrew Furlong, Medical Director</td>
</tr>
<tr>
<td>Date of Latest Approval:</td>
<td>15 February 2019 – Policy and Guideline Committee</td>
</tr>
<tr>
<td>Next Review Date:</td>
<td>February 2022</td>
</tr>
</tbody>
</table>
**CONTENTS**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong> Introduction</td>
<td>3</td>
</tr>
<tr>
<td><strong>2</strong> Policy Scope</td>
<td>3</td>
</tr>
<tr>
<td><strong>3</strong> Definitions</td>
<td>3</td>
</tr>
<tr>
<td><strong>4</strong> Roles and Responsibilities</td>
<td>3</td>
</tr>
<tr>
<td><strong>5</strong> Policy Statements, Standards, Procedures, Processes and Associated Documents</td>
<td>4</td>
</tr>
<tr>
<td><strong>6</strong> Education and Training</td>
<td>5</td>
</tr>
<tr>
<td><strong>7</strong> Process for Monitoring Compliance</td>
<td>5</td>
</tr>
<tr>
<td><strong>8</strong> Equality Impact Assessment</td>
<td>6</td>
</tr>
<tr>
<td><strong>9</strong> Supporting References, Evidence Base and Related Policies</td>
<td>6</td>
</tr>
<tr>
<td><strong>10</strong> Process for Version Control, Document Archiving and Review</td>
<td>6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Appendices</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong> Summary flow chart to be used in conjunction with the detailed information given in the guidelines</td>
<td>7</td>
</tr>
</tbody>
</table>

**REVIEW DATES AND DETAILS OF CHANGES MADE DURING THE REVIEW**

June 2013 – review of version 1- Change to new Trust format.
January 2016 – review of policy due to expire later in the year. Updated names for committees
January 2019 – change into new format. No other changes.

**KEY WORDS**

Multi-dose vials
1 INTRODUCTION

1.1 This document sets out the University Hospitals of Leicester (UHL) NHS Trusts Policy for the use multiple dose vials of injectable medication to ensure patient safety.

1.2 The majority of vials supplied by the Pharmacy Department are vials which are intended for the administration of a single dose with any remainder discarded immediately. There are however, a few vials which do contain a preservative and are intended to allow multiple doses to be withdrawn from the same vial.

1.3 In a reported incident a patient died following the cross-contamination of a multi-dose vial which had been used for another patient who had malaria. Preservatives used within the vials will not protect against contamination with blood borne infections.

1.4 The Health and Safety Executive and NHS Commissioning Board recommendation is that multi-dose vials must be avoided wherever possible.

2 POLICY SCOPE

2.1 This policy applies to all healthcare staff employed by UHL involved in the dispensing, preparation and administration of injectable medicines.

3 DEFINITIONS

3.1 Multi-dose vials of injectable medicines

Multi-dose vials are those that contain antimicrobial preservatives as stated on the label or product information and are licensed for multiple use. The most commonly used preservatives are benzyl alcohol, phenol, methyl parahydroxybenzoate and cresol.

3.2 Expiry dates

- Product expiry date is the date found on the manufacturer's package and is the date which the medicine must be used before.

- ‘In-use’ storage expiry is the expiry date once the product has been opened and used. The most common example is insulin which has a 28 day expiry after the first dose has been removed.

4 ROLES AND RESPONSIBILITIES

4.1 The executive lead responsible for this policy is the Medical Director

4.2 Clinical Management Group (CMGs) Clinical Directors and Heads of Nursing are responsible for:

a) Ensuring that all relevant staff are aware of this policy.

b) Completing the risk assessment and putting into place appropriate processes for using multi-dose vials on more than one patient within their CMG.

c) Investigating where practice has not followed this policy, ensuring these are reported on Datix.
4.3 **Medicines Optimisation Committee** is responsible for:

a) Overall monitoring of compliance of this policy through regular reporting of incidents and the annual Medicines code audit.

b) Approval of all completed risk assessments from CMGs for the use of multi-vials to be used on more than one named patient.

4.4 **Employees**

a) All staff involved in the administration of injectable medicines have a duty to follow this policy and report any concerns which may impact the safety of patients.

5 **Policy Statements**

5.1 Where possible and where practice allows vials, syringes or ampoules intended to be used as a single dose must be used in preference to multi-dose vials.

5.2 This applies to all preparations i.e. ampoules, vials, infusion bags etc and also includes occasions where a product is given non parenterally such as for flushing nasogastric tubes or diluting nebuliser solutions.

5.3. Sterile fluids intended for injection, including sodium chloride 0.9%, water or medicines which do not contain a preservative must be for **single use only**. If only part of the container is used the remainder must be discarded immediately.

5.4. Multi-dose vials may be used to prepare more than one dose. The storage time will be limited once the first dose is withdrawn from the vial. Multi-dose vials once opened must be kept refrigerated during the in-use storage time unless stated otherwise in the product information and labelled with the time and date opened. The in-use storage time may be found on the label or in the product information sheet, but if unclear advice must be sought from Pharmacy or Medicines Information. **This storage time is not the same as the expiry date stated on the label.**

5.5 Multiple dose vials where used, must be restricted for the use of a **single named patient**. Each vial must be labelled with the patient’s name and expiry date and time, using the in-use storage time found on the label or product information.

5.6. If no in-use storage time is stated, the container must be treated as if it does not contain a preservative and used for a single dose only.

5.7 If it is unclear to a practitioner as to whether the injectable container they are using contains a preservative or not, advice must be sought from pharmacy or Medicines Information extn 6491. Out of normal pharmacy department hours the on call pharmacist may be called to provide advice. If clarification cannot be provided then the practitioner must only use once and discard any remainder, treating as if a single dose.

5.8 A new sterile syringe and needle must be used for each withdrawal from a vial, even if a single dose requires more than one withdrawal.

5.9 Whatever preparation is selected, preparation and administration must be in accordance with the Trust’s IV policy (B25/2010).
Authorised exceptions:

5.10 This policy acknowledges that multi-dose preparation for one or more patients from a vial intended for single use (without a preservative) carries greater risk when undertaken in clinical areas than when undertaken in a pharmacy aseptic unit.

5.11 Within Clinical Management Groups (CMGs), any decision to use a multi dose or a vial with no preservative for more than one patient must be agreed with the CMG Lead Pharmacist, Quality and Safety Lead, Head of Service/Clinical Director and Head of Nursing. This must be supported by a full risk assessment and the risks of multi-use of vials in the clinical area concerned documented on the Trust’s risk register to be reviewed annually. (see Risk management Policy A12/2002.) The exception to this is radiopharmaceutical products which have an exemption from the Medicines and Healthcare product Regulatory Agency (MHRA).

5.12 The identified risks can be reduced/minimised with detailed procedures and training of named staff, together with audit and incident report reviews. The procedures must be approved within the CMG /Trust Policy and Guideline approval committee as appropriate.

5.13 A copy of the completed risk assessment must be sent to the Medication Safety Pharmacist for final approval at the Medicines Optimisation Committee and entry onto a Trust wide central database of exemptions to medication related policies.

6 EDUCATION AND TRAINING REQUIREMENTS

6.1 All relevant staff must have read and understood this policy and the procedures therein. If additional training is felt to be required by an area the Pharmacy Team can be contacted.

7 PROCESS FOR MONITORING COMPLIANCE

The following table lists the monitoring arrangements for this policy:

<table>
<thead>
<tr>
<th>Element to be monitored</th>
<th>Lead</th>
<th>Tool</th>
<th>Frequency</th>
<th>Reporting arrangements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Datix Incidents</td>
<td>Medication safety pharmacist</td>
<td>Datix incident reporting system</td>
<td>Regular review of incidents</td>
<td>Chief pharmacist / Medicines Optimisation Committee</td>
</tr>
<tr>
<td>relating to inappropriate use of multi dose vials</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation of practice</td>
<td>Medication safety pharmacist</td>
<td>Audits of areas</td>
<td>Qtrly</td>
<td>Medicines Optimisation Committee</td>
</tr>
<tr>
<td>Review of completed Risk assessments</td>
<td>Medication safety pharmacist</td>
<td>Risk register</td>
<td>Annual</td>
<td>Medicines Optimisation Committee</td>
</tr>
</tbody>
</table>
8 EQUALITY IMPACT ASSESSMENT

8.1 The Trust recognises the diversity of the local community it serves. Our aim therefore is to provide a safe environment free from discrimination and treat all individuals fairly with dignity and appropriately according to their needs.

8.2 As part of its development, this policy and its impact on equality have been reviewed and no detriment was identified.

9 SUPPORTING REFERENCES, EVIDENCE BASE AND RELATED POLICIES


3. Leicestershire Medicines Code

10 PROCESS FOR VERSION CONTROL, DOCUMENT ARCHIVING AND REVIEW

10.1 This document will be uploaded onto SharePoint and available for access by Staff through INsite. It will be stored and archived through this system.

10.2 This Policy will be reviewed every three years or sooner in response to clinical or risk issues.
Decision aid about using a vial on more than one occasion.
(to be used in conjunction with the detailed information given in the policy)

Appendix One

Is a preservative included in the contents listed on the label?

Yes

Is there an in-use storage time stated on the label, information leaflet or product data sheet?

Yes

Use for the in-use storage time stated, then discard.
Write patient’s name, date and time opened on the container when first used.
Subsequent use, always check date opened and that the product is still within the in-use time.

No

No / unsure

Has the container been physically opened?

Yes

Discard immediately

No

Use for single patient and discard any remaining contents

Based on the Drug and Therapeutics committee Bulletin – Lothian
University Hospital NHS Trust Hospital Pharmacist 2001:8:22-24